Curriculum Vitae

Personal information

Magali Cordaillat-Simmons

Work experience

September 2024
Present
Chaire Professeur Junior
Université Clermont Auvergne
France
Research and Graduate teaching activities

July 2024
April 2025
Founder and General Manager
MCS BioInnovation (SARL EJJM-BI)
France
Consultancy and training in microbiome science and microbiome regulatory science

May 2010
January 2024
Executive Director
Pharmabiotic Research Institute (PRI)
France
General Management of an EU-focused learned society specializing in microbiome regulatory science - expert group management, microbiome regulatory science activities and publications

October 2006
March 2009
Post-Doctoral Researcher
University of Virginia
United States
Project management, scientific and technical realization of the project; NIH grant and scientific articles writing; Scientific awareness

March 2006
July 2006
Post-Doctoral Researcher
INSERM U637
France
Project management, scientific and technical realization of the project; Scientific articles writing, scientific awareness

Education and training

- September 2013
- July 2014
- Master's degree
- Université de Strasbourg
- France
- European Pharmaceutical Regulatory Affairs

- September 2002
- December 2005
- PhD
- Université René Descartes (Paris V)
- France
- Cardiovascular Physiology and Pharmacology

- September 2001
- june 2002
- Master's degree
- Université Claude Bernard (Lyon I)
- France
- Pharmacology

Additional information

Publications

- Rodriguez J, **Cordaillat-Simmons M**, Pot B, Druart C. The regulatory framework for microbiome-based therapies: insights into European regulatory developments. NPJ Biofilms Microbiomes. 2025 Mar 28;11(1):53.
- Rodriguez J, **Cordaillat-Simmons M**, Badalato N, Berger B, Breton H, de Lahondès R, Deschasaux-Tanguy M, Desvignes C, D'Humières C, Kampshoff S, Lavelle A, Metwaly A, Quijada NM, Seegers JFML, Udocor A, Zwart H; Human Microbiome Action Consortium; Maguin E, Doré J, Druart C. Microbiome testing in Europe: navigating analytical, ethical and regulatory challenges. Microbiome. 2024 Dec 18;12(1):258.

- Rodriguez J, Hassani Z, Alves Costa Silva C, Betsou F, Carraturo F, Fasano A, Israelsen M, Iyappan A, Krag A, Metwaly A, Schierwagen R, Trebicka J, Zwart H, Doré J, and **Cordaillat-Simmons M**, Druart C; Human Microbiome Action consortium. State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi consensus. Lancet Microbe. 2025 Feb;6(2):100948.
- Benech N, Barbut F, Fitzpatrick F, Krutova M, Davies K, Druart C, **Cordaillat-Simmons M**, Heritage J, Guery B, Kuijper E; ESGCD and ESGHAMI. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023. Clin Microbiol Infect. Decembre 2023.
- Bartochowski P, Gayrard N, Bornes S, Druart C, Argilés A, **Cordaillat-Simmons M**, Duranton F. Gut-Kidney Axis Investigations in Animal Models of Chronic Kidney Disease. Toxins (Basel). September 2022.
- Paquet JC, Claus SP, **Cordaillat-Simmons M**, Mazier W, Rawadi G, Rinaldi L, Elustondo F, Rouanet A. Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From the EMA and the FDA. Front Med (Lausanne). 2021 Aug 11;8:716266.
- **Cordaillat-Simmons M**, Rouanet A, Pot B. Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med. 2020 Sep;52(9):1397-1406.
- **Cordaillat-Simmons M**, Rouanet A, Pot B. Food or Pharma: The name does make a difference. Book chapter, January 2021.
- Rouanet A, Bolca S, Bru A, Claes I, Cvejic H, Girgis H, Harper A, Lavergne SN, Mathys S, Pane M, Pot B, Shortt C, Alkema W, Bezulowsky C, Blanquet-Diot S, Chassard C, Claus SP, Hadida B, Hemmingsen C, Jeune C, Lindman B, Midzi G, Mogna L, Movitz C, Nasir N, Oberreither M, Seegers JFML, Sterkman L, Valo A, Vieville F, **Cordaillat-Simmons M**. Live Biotherapeutic Products, A Road Map for Safety Assessment. Front Med (Lausanne). 2020 Jun 19;7:237.

- Pentz ES, **Cordaillat M**, Carretero OA, Tucker AE, Sequeira Lopez ML, Gomez RA. Histone acetyl transferases CBP and p300 are necessary for maintenance of renin cell identity and transformation of smooth muscle cells to the renin phenotype. Am J Physiol Heart Circ Physiol. June 2012.
- **Cordaillat M**, Reboul C, Gaillard V, Lartaud I, Jover B, Rugale C. Plasma volume and arterial stiffness in the cardiac alterations associated with long-term high sodium feeding in rats. Am J Hypertens. April 2011.
- Fort A, **Cordaillat M**, Thollon C, Salazar G, Mechaly I, Villeneuve N, Vilaine JP, Richard S, Virsolvy A. New insights in the contribution of voltage-gated Na(v) channels to rat aorta contraction. PLoS One. October 2009.
- Gomez RA, Pentz ES, Jin X, **Cordaillat M**, Sequeira Lopez ML. CBP and p300 are essential for renin cell identity and morphological integrity of the kidney. Am J Physiol Heart Circ Physiol. May 2009.
- Gaillard V, Jover B, Casellas D, **Cordaillat M**, Atkinson J, Lartaud I. Renal function and structure in a rat model of arterial calcification and increased pulse pressure. Am J Physiol Renal Physiol. October 2008.
- Pentz ES, Lopez ML, **Cordaillat M**, Gomez RA. Identity of the renin cell is mediated by cAMP and chromatin remodeling: an in vitro model for studying cell recruitment and plasticity. Am J Physiol Heart Circ Physiol. February 2008.
- Rugale C, **Cordaillat M**, Mimran A, Jover B. Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension. J Renin Angiotensin Aldosterone Syst. December 2005.
- **Cordaillat M**, Rugale C, Casellas D, Mimran A, Jover B. Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats. Am J Physiol Regul Integr Comp Physiol. October 2005.

Projects

WP Leader on European Project : Human Microbiome Action (IHMSCSA - grant agreement No 964590) - WP6 Leader (Microbiome-based biomarkers)

Memberships

Verbal presentations as an invited speaker at International Scientific Conferences:

June-23 ISAPP Annual Meeting: The regulatory landscape of LBPs "vs." probiotics. Denver; US
May-23 59th AESGP Annual Meeting : Self-care in Europe - probiotics - what's next. Brussels; BE
Feb-23 Probiota 2023: Panel discussion on "Pharmabiotics". Barcelona; ES
Mar-22 Probiota 2022: The Microbiome: An example on how regulatory science paves the way for innovative therapies. Copenhagen; DK
Nov-21 Kisaco Research Microbiome Connect US: Panel Discussion with Peter Marks (CBER Director-FDA): Biotechs Meet Regulators. Boston; US
Sept-21 Probiotics Prebiotics & New Foods: The Regulatory Paths for Probiotics "versus" Live Biotherapeutic Products. Rome; IT
Jun-21 MEDICEN: Regulatory Aspects for Microbiome-based Medicinal Products. Paris; FR
Apr-21 Pharmabiotics 2021: Panel Discussion: Looking at Microbiota-Gut-Interorgan-Axes within a Regulatory Context. Online
Nov-20 IPC 2020: Clarification on Terminologies and Respective Regulatory Statuses - where do pharmabiotics fall? Online
Oct-20 Pharmabiotics Online 2020: Live Biotherapeutic Products (LBPs), A Road Map for Safety Assessment. Online
Mar-20 Pharmabiotics 2020: Microbiotic Medicinal Products (MMPs): What can we learn from the regulatory frameworks of other innovative products. Paris; FR
Feb-20 Pro-PreBiotics: Clarifying the Expectations of Drug Authorities for Microbiotic Medicinal Products. Kyiv; UA

May-19 Global Engage Microbiome Forum: Clarifying the Expectations of Drug Authorities for Microbiotic Medicinal Products - A European Regulatory Perspective. Rotterdam; NL
Mar-19 Pharmabiotics 2019: Putting into perspective the international Regulatory framework in food and pharma. Paris; FR
Jan-19 Microbiome Movement Drug Dev EU: Regulatory Challenges for registering Live Biotherapeutic Products in Europe. Paris; FR
June-18 Microbiome Movement Drug Dev US: Regulatory Challenges for registering Live Biotherapeutic Products in Europe. Boston; US
May-20 MEDICEN: Regulatory environment surrounding Microbiotic Medicinal Products in the EU: Lessons learnt from the LBPs' footprint. Paris; FR
Mar-18 Global Engage Microbiome Forum: Roundtable Discussion: Regulatory Aspects for LBPs. Rotterdam; NL
Mar-18 Pharmabiotics 2018: An Innovative Approach in Absence of Clear Regulatory Framework for LBPs at the EU Level. Paris; FR
Feb-18 Probiotiques et Microbiote Intestinal: Regulatory Challenges for registering Live Biotherapeutic Products in Europe. Lyon; FR
Feb-18 North America Microbiome Congress: Regulatory Challenges for registering Live Biotherapeutic Products in Europe. San Diego; US
Feb-18 Microbiome Movement Drug Dev EU: Regulatory Challenges for registering Live Biotherapeutic Products in Europe. Paris; FR

Other Relevant Information

2015 - 2019 : Member of the French and European Pharmacopoeia ; Participation in the Expert Group on Live Biotherapeutic Products (drafting of Monograph 3053 and chapter 2.6 36 and 2.6.38)